Characterization and vaccine potential of Fasciola gigantica saposin-like protein 1 (SAP-1)

Kueakhai, Pornanan; Changklungmoa, Narin; Waseewiwat, Pinkamon; Thanasinpaiboon, Thanaporn; Cheukamud, Werachon; Chaichanasak, Pannigan; Sobhon, Prasert

doi:10.1016/j.vetpar.2016.12.009

Cited by 7 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All vaccinated groups could induce both T-helper 1 (IgG2a) and Th2 (IgG1), with Th2 (IgG1) predominating. The mixed Th2/Th1 immune responses with Th2 predominating have been reported for several antigen vaccines, including rFhCatL1 [ 15 , 48 ], rFgPrx [ 26 ], rFgCatL1G [ 28 ], rFgGST26 [ 11 ], rFgCatL1H [ 13 ], rFgCatB3 and rFhCatB3 [ 10 , 49 ], rFgSAP-1 [ 21 ], rFgSAP-2 [ 22 ], and rFgLAP [ 18 ]. Furthermore, both single and combined vaccinated mice in this study exhibited a strong correlation between the numbers of worm recoveries and the levels of both types of antibodies (IgG1 and IgG2a) at infection and termination, which is similar to several previous studies [ 10 , 13 , 14 ].…”

Section: Discussionmentioning

confidence: 99%

“…Vaccination is a more cost-effective, sustainable, and environmentally friendly method for controlling the disease and is considered safe for animals and consumers [8]. Previous publications showed that several Fasciola antigens have been tested for the vaccine against fasciolosis, including fatty acid binding protein (FABP) [9], cathepsins B2 and B3 [10], glutathione S-transferase (GST) [11,12], cathepsin L [13][14][15][16], tetraspanin 2 (TSP2) [17], leucine aminopeptidase (LAP) [18][19][20], and saposinlike protein (SAP) [21][22][23][24][25]. Immunizations with recombinant proteins from F. gigantica, including 2-Cys peroxiredoxin (Prx) in mice and buffaloes [26,27], cathepsin L1 in mice, cattle, and sheep [14][15][16], cathepsin L1H in mice [13], cathepsin L1G in mice [28], GST in mice and buffalo [11,12], superoxide dismutase (SOD) in mice [29], cathepsin B2 and B3 [10], LAP in mice [18], SAP-1 in mice [21], and SAP-2 in mice [22] have been shown to protect against F. gigantica infection with a limited outcome.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Immunizations with recombinant proteins from F . gigantica , including 2-Cys peroxiredoxin (Prx) in mice and buffaloes [ 26 , 27 ], cathepsin L1 in mice, cattle, and sheep [ 14 , 15 , 16 ], cathepsin L1H in mice [ 13 ], cathepsin L1G in mice [ 28 ], GST in mice and buffalo [ 11 , 12 ], superoxide dismutase (SOD) in mice [ 29 ], cathepsin B2 and B3 [ 10 ], LAP in mice [ 18 ], SAP-1 in mice [ 21 ], and SAP-2 in mice [ 22 ] have been shown to protect against F . gigantica infection with a limited outcome.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Combination Vaccines of Fasciola gigantica Saposin-like Protein-2 and Leucine Aminopeptidase

et al. 2023

Self Cite

View full text Add to dashboard Cite

Saposin-like protein-2 (SAP-2) and leucine aminopeptidase (LAP) are major proteins involved in the digestive process of Fasciola gigantica (Fg). Both SAP-2 and LAP are highly expressed in F. gigantica; therefore, they could be vaccine candidates for fasciolosis. The aims of this study are (1) to observe the tissue expression of F. gigantica SAP-2 (FgSAP-2) and F. gigantica LAP (FgLAP) in F. gigantica by indirect immunofluorescence technique under confocal microscopy and (2) to test the vaccine potentials of individual and combined recombinant (r) FgSAP-2 and rFgLAP against F. gigantica in Imprinting Control Region (ICR) mice (n = 10 per group). By indirect immunofluorescence-confocal microscopy, FgSAP-2 and FgLAP were localized in the caecal epithelium but at different sites: FgSAP-2 appeared in small granules that are distributed in the middle and lower parts of the cytoplasm of epithelial cells, while FgLAP appeared as a line or zone in the apical cytoplasm of caecal epithelial cells. For vaccine testing, the percent protection of combined rFgSAP-2 and rFgLAP vaccines against F. gigantica was at 80.7 to 81.4% when compared with aluminum hydroxide (alum) adjuvant and unimmunized controls, respectively. The levels of IgG1 and IgG2a in the sera were significantly increased in single and combine vaccinated groups compared with the control groups. Vaccinated mice showed reduced liver damage when compared with control groups. This study indicates that the combined rFgSAP-2 and rFgLAP vaccine had a higher vaccine potential than a single vaccine. These results support the further testing and application of this combined vaccine against F. gigantica infection in farmed livestock animals.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Combination Vaccines of Fasciola gigantica Saposin-like Protein-2 and Leucine Aminopeptidase

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Saposins are known to be immunogenic in S. mansoni infection ( 38 ) and are candidate serodiagnostic antigens in S. japonicum infection ( 39 ). Recombinant saposins from the liver flukes Fasciola hepatica and Fasciola gigantica confer protection against challenge infection in animal models ( 40 , 41 ). Saposins from the gastrodermis of S. mansoni were tested as subunit vaccines in the mouse model and did not confer protection ( 38 ), but based on these findings herein, the S. haematobium proteins should be tested before final down-selection.…”

Section: Discussionmentioning

confidence: 99%

Immunomics-Guided Antigen Discovery for Praziquantel-Induced Vaccination in Urogenital Human Schistosomiasis

et al. 2021

View full text Add to dashboard Cite

Despite the enormous morbidity attributed to schistosomiasis, there is still no vaccine to combat the disease for the hundreds of millions of infected people. The anthelmintic drug, praziquantel, is the mainstay treatment option, although its molecular mechanism of action remains poorly defined. Praziquantel treatment damages the outermost surface of the parasite, the tegument, liberating surface antigens from dying worms that invoke a robust immune response which in some subjects results in immunologic resistance to reinfection. Herein we term this phenomenon Drug-Induced Vaccination (DIV). To identify the antigenic targets of DIV antibodies in urogenital schistosomiasis, we constructed a recombinant proteome array consisting of approximately 1,000 proteins informed by various secretome datasets including validated proteomes and bioinformatic predictions. Arrays were screened with sera from human subjects treated with praziquantel and shown 18 months later to be either reinfected (chronically infected subjects, CI) or resistant to reinfection (DIV). IgG responses to numerous antigens were significantly elevated in DIV compared to CI subjects, and indeed IgG responses to some antigens were completely undetectable in CI subjects but robustly recognized by DIV subjects. One antigen in particular, a cystatin cysteine protease inhibitor stood out as a unique target of DIV IgG, so recombinant cystatin was produced, and its vaccine efficacy assessed in a heterologous Schistosoma mansoni mouse challenge model. While there was no significant impact of vaccination with adjuvanted cystatin on adult worm numbers, highly significant reductions in liver egg burdens (45-55%, P<0.0001) and intestinal egg burdens (50-54%, P<0.0003) were achieved in mice vaccinated with cystatin in two independent trials. This study has revealed numerous antigens that are targets of DIV antibodies in urogenital schistosomiasis and offer promise as subunit vaccine targets for a drug-linked vaccination approach to controlling schistosomiasis.

show abstract

Prospects for liver fluke vaccines

Zhang

Sun

Zheng

2021

Experimental Parasitology

View full text Add to dashboard Cite

Characterization and vaccine potential of Fasciola gigantica saposin-like protein 1 (SAP-1)

Cited by 7 publications

References 29 publications

Combination Vaccines of Fasciola gigantica Saposin-like Protein-2 and Leucine Aminopeptidase

Combination Vaccines of Fasciola gigantica Saposin-like Protein-2 and Leucine Aminopeptidase

Immunomics-Guided Antigen Discovery for Praziquantel-Induced Vaccination in Urogenital Human Schistosomiasis

Prospects for liver fluke vaccines

Contact Info

Product

Resources

About